文献速递免疫规划传染病防控与疫情报告

婴儿基础免疫中DTaP5-HB-IPV-Hib与C群脑膜炎球菌结合疫苗同时接种的随机临床试验

Randomized clinical trial of DTaP5-HB-IPV-Hib vaccine administered concomitantly with meningococcal serogroup C conjugate vaccines during the primary infant series.
PubMed 文献 · Vaccine · 2020-07-10

这项3期开放标签随机试验在284名英国健康婴儿中评估DTaP5-HB-IPV-Hib与两种C群脑膜炎球菌结合疫苗(MCC-TT或MCC-CRM)同时接种的相容性。婴儿在2、3、4月龄接种DTaP5-HB-IPV-Hib,并在3、4月龄随机加用MCC-TT或MCC-CRM。结果显示MCC血清保护率在两组均较高,且联合疫苗对白喉、破伤风、脊髓灰质炎和百日咳抗原的免疫应答良好,支持该联合疫苗可用于2、3、4月龄基础免疫程序。

要点

  • DTaP5-HB-IPV-Hib可与两剂MCC疫苗同时用于2、3、4月龄婴儿基础免疫。
  • MCC-TT组和MCC-CRM组MCC血清保护率在首剂后分别为100%和96.4%。
  • 所有受试者对白喉、破伤风、脊髓灰质炎1-3型均达血清保护,百日咳抗原血清应答率≥90.4%。

核心结论

  • DTaP5-HB-IPV-Hib与2剂MCC疫苗同时接种时,在2、3、4月龄婴儿基础免疫程序中可有效使用。

研究设计与样本

  • 3期、开放标签、随机对照试验,纳入284名来自英国11个中心的健康婴儿。
  • 婴儿在2、3、4月龄接种DTaP5-HB-IPV-Hib,2和4月龄接种PCV13,12月龄接种Hib-MCC和麻腮风疫苗。
  • 参与者按1:1随机在3和4月龄接种MCC-TT(n=141)或MCC-CRM(n=143),主要结局为MCC血清保护率(兔补体血清杀菌抗体滴度≥8的百分比)。

主要发现

  • 符合方案分析中,MCC-TT组和MCC-CRM组首剂后1个月MCC血清保护率分别为100%和96.4%,第二剂后分别为100%和99.1%,第三剂(加强)后分别为100%和97.3%。
  • 完成3剂DTaP5-HB-IPV-Hib后1个月,MCC-TT组和MCC-CRM组抗PRP IgG血清保护率(≥0.15 µg/mL)分别为97.8%和100%,抗HBs血清保护率(≥10 mIU/mL)分别为96.8%和96.3%。
  • 所有受试者对白喉和破伤风(≥0.01 IU/mL)及脊髓灰质炎病毒1、2、3型(≥8稀释度)均达血清保护,对全部百日咳抗原的血清应答率≥90.4%。
  • MCC-CRM组1名参与者发生2例与疫苗相关的严重不良事件(一过性严重腹痛和哭闹);任何剂次后发热≥38°C的发生率为10.9%。

关键数值与推荐

  • MCC血清保护定义为兔补体血清杀菌抗体滴度≥8。
  • 抗PRP IgG血清保护定义为≥0.15 µg/mL。
  • 抗HBs血清保护定义为≥10 mIU/mL。
  • 白喉和破伤风血清保护定义为≥0.01 IU/mL,脊髓灰质炎病毒血清保护定义为≥8稀释度。

临床怎么用

  • 在2、3、4月龄婴儿基础免疫程序中,DTaP5-HB-IPV-Hib可与2剂MCC疫苗同时接种,不降低MCC血清保护率。
  • 同时接种时联合疫苗对白喉、破伤风、脊髓灰质炎、百日咳、Hib和乙肝的免疫应答良好,可简化接种流程。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Concomitant administration of vaccines simplifies delivery. DTaP5-HB-IPV-Hib is a fully liquid, combination vaccine against 6 diseases. This study evaluated the compatibility of DTaP5-HB-IPV-Hib with 2 different meningococcus group C conjugate (MCC) vaccines in infants. METHODS: In a phase 3, open-label study, 284 healthy infants from 11 UK centres received DTaP5-HB-IPV-Hib at age 2, 3, and 4 months; 13-valent pneumococcal conjugate vaccine (PCV13) at 2 and 4 months; a Haemophilus influenzae type b (Hib)-MCC vaccine and a measles/mumps/rubella vaccine at 12 months. Participants were randomised 1:1 to receive either an MCC-detoxified tetanus toxin vaccine (MCC-TT; n = 141) or an MCC-Corynebacterium diphtheriae CRM197 protein vaccine (MCC-CRM; n = 143) at 3 and 4 months. The primary outcome was seroprotection rate (SPR) to MCC (percent with rabbit complement serum bactericidal antibody titer ≥8). RESULTS: Per protocol analysis, MCC SPRs were 100 and 96.4 one month after the first dose, 100 and 99.1 after the second dose, and 100 and 97.3 after the third (booster) dose of MCC in the MCC-TT and MCC-CRM groups, respectively. One month after all 3 doses of DTaP5-HB-IPV-Hib, immunoglobulin G anti-polyribosylribitol phosphate SPRs (% ≥0.15 µg/mL) were 97.8 in the MCC-TT group and 100 in the MCC-CRM group; anti-hepatitis B antigen SPRs (% ≥10 mIU/mL) were 96.8 and 96.3 in the MCC-TT and MCC-CRM groups, respectively. All participants were seroprotected against diphtheria and tetanus (≥0.01 IU/mL) and poliovirus types 1, 2, and 3 (≥8 dilution), and seroresponse rates to all pertussis antigens were ≥90.4%. Two vaccine-related serious adverse events (transient severe abdominal pain and crying) occurred concomitantly in 1 participant in the MCC-CRM group. Adverse event rates were similar to other studies of DTaP5-HB-IPV-Hib, with pyrexia ≥38 °C in 10.9% of participants following any dose. CONCLUSIONS: DTaP5-HB-IPV-Hib can be effectively used in a 2-, 3-, and 4-month infant priming schedule when given with 2 doses of MCC.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Oliver JL, Sadorge C, Boisnard F, et al. Randomized clinical trial of DTaP5-HB-IPV-Hib vaccine administered concomitantly with meningococcal serogroup C conjugate vaccines during the primary infant series. Vaccine. 2020. PMID: 32654902. doi:10.1016/j.vaccine.2020.06.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。